Helius Medical Technologies to Present at Upcoming Healthcare Investor Conferences in September
Helius Medical Technologies, Inc. (Nasdaq:HSDT) announced that its executives will present at two healthcare conferences this September. The first is the H.C. Wainwright 24th Annual Global Investment Conference (September 12-14, 2022), available on demand. The second is the Ladenburg Thalmann Healthcare Conference in New York City on September 29, 2022, at 10:00 AM ET. Helius focuses on neurological wellness and offers the Portable Neuromodulation Stimulator (PoNS), a non-surgical device aimed at improving balance and gait for patients with multiple sclerosis and traumatic brain injury.
- None.
- None.
NEWTOWN, Pa., Sept. 06, 2022 (GLOBE NEWSWIRE) -- Helius Medical Technologies, Inc. (Nasdaq:HSDT) (“Helius” or the “Company”), a neurotech company focused on neurological wellness, today announced that Dane Andreeff, President and Chief Executive Officer, and Jeff Mathiesen, Chief Financial Officer, will present at two upcoming healthcare conferences as follows:
| H.C. Wainwright 24th Annual Global Investment Conference (Virtual) | ||
| Dates: | Monday, September 12, 2022 – Wednesday, September 14, 2022 | |
| Time: | On demand, beginning at 7:00 AM ET* | |
| * For H.C. Wainwright Conference registrants. | ||
| Ladenburg Thalmann 2022 Healthcare Conference (New York City) | ||
| Date: | Thursday, September 29, 2022 | |
| Time: | 10:00 AM ET | |
About Helius Medical Technologies, Inc.
Helius Medical Technologies is a leading neurotech company in the medical device field focused on neurologic deficits using non-implantable platform technologies that amplify the brain’s ability to compensate and promotes neuroplasticity, aiming to improve the lives of people dealing with neurologic diseases. The Company’s first commercial product is the Portable Neuromodulation Stimulator (PoNS). For more information, visit www.heliusmedical.com.
About the PoNS Device and PoNS Therapy
The Portable Neuromodulation Stimulator (PoNS) is an innovative non-surgical medical device, inclusive of a controller and mouthpiece, which delivers electrical stimulation to the surface of the tongue to improve balance and gait. The PoNS device is indicated for use in the United States as a short-term treatment of gait deficit due to mild-to-moderate symptoms from multiple sclerosis (“MS”) and is to be used as an adjunct to a supervised therapeutic exercise program in patients 22 years of age and over by prescription only. Helius is advancing PoNS post-approval research in MS through a recently launched Therapeutic Experience Program (TEP) designed to partner with neurologists and neurorehabilitation therapists at 10-12 US centers of excellence, who express an interest in becoming “early adopters” of PoNS therapy. For more information visit www.ponstherapy.com.
PoNS is also authorized for sale in Canada for two indications: (i) for use as a short-term treatment (14 weeks) of chronic balance deficit due to mild-to-moderate traumatic brain injury (“mmTBI”) and is to be used in conjunction with physical therapy; and (ii) for use as a short term treatment (14 weeks) of gait deficit due to mild and moderate symptoms from MS and is to be used in conjunction with physical therapy. PoNS is also authorized for sale in Australia for short term use by healthcare professionals as an adjunct to a therapeutic exercise program to improve balance and gait.
Investor Relations Contact
Lisa M. Wilson, In-Site Communications, Inc.
T: 212-452-2793
E: lwilson@insitecony.com
FAQ
When will HSDT present at the H.C. Wainwright 24th Annual Global Investment Conference?
What is the date and time of HSDT's presentation at the Ladenburg Thalmann Healthcare Conference?
What is the focus of HSDT's Portable Neuromodulation Stimulator (PoNS) device?
Is HSDT's PoNS device authorized for use outside the United States?
